5 Questions Novo Nordisk Must Answer to Drive Its Stock Higher

Novo Nordisk experienced a significant setback as its shares fell nearly 30% in the fourth quarter. This decline was primarily attributed to disappointing clinical trial data and other concerns that have raised questions about the company's future direction. Bank of America has taken a closer look at Novo Nordisk's earnings, highlighting the need for the company to address several key issues to regain investor confidence and drive its stock higher. The focus is on how Novo Nordisk plans to navigate these challenges and what strategies it will implement to ensure sustainable growth and profitability moving forward.